U.S. markets closed

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.6900+0.3400 (+7.82%)
At close: 4:00PM EDT

4.7200 +0.03 (0.64%)
After hours: 6:30PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.3500
Open4.7200
Bid4.4000 x 2900
Ask4.8000 x 1000
Day's Range4.3700 - 5.8600
52 Week Range2.3000 - 12.5200
Volume8,560,795
Avg. Volume2,814,473
Market Cap22.597M
Beta (5Y Monthly)1.72
PE Ratio (TTM)N/A
EPS (TTM)-5.8000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
    PR Newswire

    Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

    Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions. The Company has also granted the underwriter a 30-day option to purchase up to an additional 455,454 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 30, 2021, subject to satisfaction of customary closing conditions.

  • Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
    PR Newswire

    Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

    Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 1,764,705 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions. The Company has also granted the underwriter a 30-day option to purchase up to an additional 264,705 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 30, 2021, subject to satisfaction of customary closing conditions.

  • TheStreet.com

    5 Top Stock Gainers for Tuesday: Dolphin Entertainment, Benitec

    Dolphin Entertainment, Benitec Biopharma, BioLife Solutions, Netflix and Genius Entertainment are five top stock gainers for Tuesday.